TW202228760A - 治療黑素皮質素-4受體路徑相關病症之方法 - Google Patents

治療黑素皮質素-4受體路徑相關病症之方法 Download PDF

Info

Publication number
TW202228760A
TW202228760A TW110135665A TW110135665A TW202228760A TW 202228760 A TW202228760 A TW 202228760A TW 110135665 A TW110135665 A TW 110135665A TW 110135665 A TW110135665 A TW 110135665A TW 202228760 A TW202228760 A TW 202228760A
Authority
TW
Taiwan
Prior art keywords
arg
cys
ala
phe
seq
Prior art date
Application number
TW110135665A
Other languages
English (en)
Chinese (zh)
Inventor
德 皮洛格 雷納德斯 H T 凡
阿拉斯戴爾 加菲
巴維 P 薩
Original Assignee
美商律森製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商律森製藥股份有限公司 filed Critical 美商律森製藥股份有限公司
Publication of TW202228760A publication Critical patent/TW202228760A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
TW110135665A 2020-09-24 2021-09-24 治療黑素皮質素-4受體路徑相關病症之方法 TW202228760A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063082867P 2020-09-24 2020-09-24
US63/082,867 2020-09-24

Publications (1)

Publication Number Publication Date
TW202228760A true TW202228760A (zh) 2022-08-01

Family

ID=80845850

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110135665A TW202228760A (zh) 2020-09-24 2021-09-24 治療黑素皮質素-4受體路徑相關病症之方法

Country Status (13)

Country Link
US (1) US20240058414A1 (https=)
EP (1) EP4216979A4 (https=)
JP (1) JP2023542985A (https=)
KR (1) KR20230095956A (https=)
CN (1) CN116507353A (https=)
AR (1) AR123603A1 (https=)
AU (1) AU2021350017A1 (https=)
CA (1) CA3192873A1 (https=)
CL (1) CL2023000823A1 (https=)
CO (1) CO2022009561A2 (https=)
MX (1) MX2023003360A (https=)
TW (1) TW202228760A (https=)
WO (1) WO2022067086A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023308310A1 (en) * 2022-07-12 2025-01-16 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
EP4618952A2 (en) * 2022-11-18 2025-09-24 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
WO2025106751A1 (en) * 2023-11-14 2025-05-22 Rhythm Pharmaceuticals, Inc. Combinations of a potassium channel activator and an mc4r agonist and related methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2286825T3 (pl) * 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
MA43040A (fr) * 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4

Also Published As

Publication number Publication date
CL2023000823A1 (es) 2023-09-15
AU2021350017A1 (en) 2023-05-04
JP2023542985A (ja) 2023-10-12
AU2021350017A9 (en) 2024-10-03
MX2023003360A (es) 2023-06-23
US20240058414A1 (en) 2024-02-22
EP4216979A1 (en) 2023-08-02
WO2022067086A1 (en) 2022-03-31
CN116507353A (zh) 2023-07-28
EP4216979A4 (en) 2024-11-06
AR123603A1 (es) 2022-12-21
CO2022009561A2 (es) 2022-07-19
CA3192873A1 (en) 2022-03-31
KR20230095956A (ko) 2023-06-29

Similar Documents

Publication Publication Date Title
JP7752373B2 (ja) メラノコルチン4受容体経路関連障害を治療する方法
TW202228760A (zh) 治療黑素皮質素-4受體路徑相關病症之方法
US10167312B2 (en) Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
US20260001915A1 (en) Methods for treating obesity with an mc4r agonist
RU2785889C1 (ru) Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4
HK40077660A (en) Melanocortin-4 receptor agonists for the treatment of disorders characterised by pomc gene hypermethylation
HK40073416A (en) Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers